{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:07:06Z","timestamp":1791655626200,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01536-x","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:54:53Z","timestamp":1750834493000},"page":"1139-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct04079257","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-4919","authenticated-orcid":false,"given":"Mendy","family":"ter Avest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M. C.","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P. W. J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"3","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"18","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;18(3):17028.","journal-title":"Nat Rev Dis Primers"},{"key":"1536_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/TCRM.S3334","volume":"5","author":"R Kelly","year":"2009","unstructured":"Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manage. 2009;5:911\u201321.","journal-title":"Ther Clin Risk Manage."},{"issue":"4","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","volume":"73","author":"J Takeda","year":"1993","unstructured":"Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703\u201311.","journal-title":"Cell"},{"issue":"18","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"key":"1536_CR5","unstructured":"Eculizumab. Summary of product characteristics. European Medicines Agency; 2012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed 19 Apr 2024."},{"key":"1536_CR6","unstructured":"US Food and Drug Administration. Drug approval package Soliris (eculizumab). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/125166s0000toc.cfm. [Accessed 27 May 2025]."},{"issue":"25","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786\u201392.","journal-title":"Blood"},{"issue":"8","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/0272989X14539731","volume":"34","author":"D Coyle","year":"2014","unstructured":"Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014;34(8):1016\u201329.","journal-title":"Med Decis Making"},{"issue":"2","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/ndt\/gfac056","volume":"38","author":"M Ter Avest","year":"2023","unstructured":"Ter Avest M, Bouwmeester RN, Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel L, et al. Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrol Dial Transplant. 2023;38(2):362\u201371.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","volume":"55","author":"KL Gill","year":"2016","unstructured":"Gill KL, Machavaram KK, Rose RH, Chetty M. Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet. 2016;55(7):789\u2013805.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1536_CR11","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/bcp.14627","volume":"87","author":"C Passot","year":"2021","unstructured":"Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, et al. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study. Br J Clin Pharmacol. 2021;87(5):2236\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/cpt.686","volume":"102","author":"E Volokhina","year":"2017","unstructured":"Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, et al. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102(4):671\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","volume":"160","author":"EB Volokhina","year":"2015","unstructured":"Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015;160(2):237\u201343.","journal-title":"Clin Immunol"},{"issue":"7","key":"1536_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2(7): e51.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1536_CR15","unstructured":"Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey data. Hyattsville (MD): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2022."},{"issue":"8","key":"1536_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet"},{"key":"1536_CR17","unstructured":"European Medicines Agency (EMA). CHMP extension of indication variation assessment report. London: European Medicines Agency (EMA); 2017."},{"issue":"7","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes D, Langemeijer S, Schols SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307\u201315.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","volume":"6","author":"K Mizuno","year":"2022","unstructured":"Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022;6(5):1454\u201363.","journal-title":"Blood Adv"},{"key":"1536_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CEOR.S346816","volume":"14","author":"WY Cheng","year":"2022","unstructured":"Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Kunzweiler C, et al. Real-world eculizumab dosing patterns among patients with paroxysmal nocturnal hemoglobinuria in a US population. Clinicoecon Outcomes Res. 2022;14:357\u201369.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfae244","volume":"40","author":"M Ter Avest","year":"2025","unstructured":"Ter Avest M, Duineveld C, Bouwmeester RN, Baas LM, van den Heuvel L, Langemeijer SMC, et al. Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome. Nephrol Dial Transplant. 2025;40(3):598\u2013601.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1536_CR23","first-page":"1340","volume":"93","author":"AD Kulagin","year":"2021","unstructured":"Kulagin AD, Bakirov BA, Davydkin IL, Elykomov IV, Konstantinova TS, Korobkin AV, et al. The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria: results of a phase III randomized open-label comparative clinical trial. Ter Arkh. 2021;93(11):1340\u20138.","journal-title":"Ter Arkh"},{"issue":"5","key":"1536_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"R Peffault de Latour","year":"2015","unstructured":"Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775\u201383.","journal-title":"Blood"},{"issue":"7","key":"1536_CR25","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26176","volume":"96","author":"AG Kulasekararaj","year":"2021","unstructured":"Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol. 2021;96(7):E232\u20135.","journal-title":"Am J Hematol"},{"issue":"4","key":"1536_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909.","journal-title":"PLoS ONE"},{"key":"1536_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A Position Paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.","journal-title":"Front Immunol"},{"issue":"2","key":"1536_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra2201664","volume":"387","author":"R Notaro","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160\u20136.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01536-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:39:55Z","timestamp":1757198395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01536-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"22 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicole C.A.J. van de Kar and BvdH are members of the European Reference Network for Rare Kidney Diseases (ERKNet)-Project No 739532. Nicole C.A.J. van de Kar received consultancy fees from Roche Pharmaceuticals, Alexion, and Novartis and is a sub-investigator in the APL2-C3G trial, Apellis. Rob ter Heine has received research funding from Amgen. Mendy ter Avest, Saskia M.C. Langemeijer, Lambertus P.W.J van den Heuvel, and Laura M. Baas have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Ethics approval number: NL69637.091.19, 22 July, 2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The participants of this study did not give written consent for their data to be shared publicly","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"See Electronic Supplementary Material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MtA, SL, and RtH designed the research. MtA performed the research. LB analyzed the samples. MtA wrote the paper. Each author contributed important intellectual content during manuscript drafting or revision and all authors approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}